These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 20647526)
1. Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia? Mitchell AJ; Monge-Argilés JA; Sánchez-Paya J Pract Neurol; 2010 Aug; 10(4):202-7. PubMed ID: 20647526 [TBL] [Abstract][Full Text] [Related]
2. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Herukka SK; Hallikainen M; Soininen H; Pirttilä T Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
5. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. van Rossum IA; Vos S; Handels R; Visser PJ J Alzheimers Dis; 2010; 20(3):881-91. PubMed ID: 20413876 [TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice. Parnetti L; Lanari A; Saggese E; Spaccatini C; Gallai V Neurol Sci; 2003 Oct; 24(3):199-200. PubMed ID: 14598086 [TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456 [TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538 [TBL] [Abstract][Full Text] [Related]
12. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Andersson C; Blennow K; Almkvist O; Andreasen N; Engfeldt P; Johansson SE; Lindau M; Eriksdotter-Jönhagen M Neurobiol Aging; 2008 Oct; 29(10):1466-73. PubMed ID: 17512092 [TBL] [Abstract][Full Text] [Related]
13. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530 [TBL] [Abstract][Full Text] [Related]
14. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Eckerström C; Andreasson U; Olsson E; Rolstad S; Blennow K; Zetterberg H; Malmgren H; Edman A; Wallin A Dement Geriatr Cogn Disord; 2010; 29(4):294-300. PubMed ID: 20389071 [TBL] [Abstract][Full Text] [Related]
15. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432 [TBL] [Abstract][Full Text] [Related]
16. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035 [TBL] [Abstract][Full Text] [Related]
17. Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. Koedam EL; van der Vlies AE; van der Flier WM; Verwey NA; Koene T; Scheltens P; Blankenstein MA; Pijnenburg YA Alzheimers Dement; 2013 May; 9(3):269-75. PubMed ID: 22846628 [TBL] [Abstract][Full Text] [Related]
18. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109 [TBL] [Abstract][Full Text] [Related]
19. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783 [TBL] [Abstract][Full Text] [Related]
20. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]